- Home
- OBK vs ELVN Comparison
OBK vs ELVN Comparison
Compare OBK & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBK | ELVN |
|---|---|---|
| Founded | 1912 | 2016 |
| Country | United States | United States |
| Employees | 1031 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OBK | ELVN |
|---|---|---|
| Price | $39.04 | $17.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $43.00 | $41.20 |
| AVG Volume (30 Days) | 136.7K | ★ 632.8K |
| Earning Date | 01-21-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $325,588,000.00 | N/A |
| Revenue This Year | $13.94 | N/A |
| Revenue Next Year | $6.04 | N/A |
| P/E Ratio | $20.41 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.80 | $13.30 |
| 52 Week High | $41.17 | $25.37 |
Technical Indicators
Market Signals| Indicator | OBK | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 75.34 | 33.61 |
| Support Level | $37.33 | $17.31 |
| Resistance Level | $39.14 | $20.47 |
| Average True Range (ATR) | 0.88 | 1.39 |
| MACD | 0.27 | -0.41 |
| Stochastic Oscillator | 94.61 | 6.66 |
Price Performance
Historical ComparisonAbout OBK Origin Bancorp Inc.
Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.